Novo Nordisk A/S (Novo Nordisk A/S) Total Stockholders Equity

: $15,591 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $15,591 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Novo Nordisk A/S's Book Value per Share for the quarter that ended in Dec. 2023 was $3.50. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Novo Nordisk A/S's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.25.

Novo Nordisk A/S Total Stockholders Equity Historical Data

The historical data trend for Novo Nordisk A/S's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

8,566.69

10,355.01

10,750.04

11,887.68

15,590.95

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity																11,887.68	11,489.03	13,165.65	13,307.81	15,590.95

Novo Nordisk A/S (NYSE:NVO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Novo Nordisk A/S's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(15590.946	-	0)	/	4458.29
	=	3.50

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Novo Nordisk A/S's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(947.797	+	3003.453)	/	15590.946
	=	0.25

Novo Nordisk A/S Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.